Ser Yee Lee1, T Peter Kingham2, Maria D LaGratta3, Jose Jessurun4, Daniel Cherqui5, William R Jarnagin2, Michael D Kluger6. 1. Department of Surgery, Memorial Sloan Kettering Cancer Center, 1275 York Avenue, New York, NY 10065, United States; Department of Hepatopancreatobiliary and Transplant Surgery, Singapore General Hospital, Singapore. 2. Department of Surgery, Memorial Sloan Kettering Cancer Center, 1275 York Avenue, New York, NY 10065, United States. 3. New York-Presbyterian Hospital - Weill Cornell Medical Center, Diagnostic Radiology, 1305 York Avenue, New York, NY 10021, United States. 4. New York Presbyterian Hospital - Weill Cornell Medical College, Surgical Pathology, 525 East 68th Street, New York, NY 10065, United States. 5. Hôpital Paul Brousse, Centre Hépato-Biliaire, Villejuif, France. 6. New York Presbyterian Hospital Columbia Presbyterian Medical Center, Department of Surgery, 161 Fort Washington Avenue 823, New York, NY 10024, United States. Electronic address: mk2462@cumc.columbia.edu.
Abstract
BACKGROUND: Hepatocellular adenoma (HCA) is the second most common benign liver neoplasm and occurs predominantly in women in their reproductive years. Positron emission tomography (PET) using [18F] fluorodeoxyglucose (FDG) is commonly used in cancer staging, surveillance and evaluation of treatment response. PET-avid HCA are rare and can be falsely interpreted as malignancies. METHODS: A retrospective review of four institutions' database was performed to identify the PET-avid HCAs with clinico-pathological correlation. RESULTS: Nine patients with histological proven PET-avid HCA was identified. Eight out of 9 patients were female with a median age at diagnosis of 44 years. All patients' tumors with available histological subtyping (8/8) were HNF1-α mutated and had no inflammatory changes; 6 out the 9 lesions had prominent (>50%) steatotic changes. CONCLUSION: Hepatocellular adenomas, specifically the HNF1-α subtype, can cause false-positive PET findings when seeking to identify malignancy. Concomitantly, PET-CT may have the potential to identify the HCA histopathologic variant with the lowest malignant and hemorrhagic potential.
BACKGROUND:Hepatocellular adenoma (HCA) is the second most common benign liver neoplasm and occurs predominantly in women in their reproductive years. Positron emission tomography (PET) using [18F] fluorodeoxyglucose (FDG) is commonly used in cancer staging, surveillance and evaluation of treatment response. PET-avid HCA are rare and can be falsely interpreted as malignancies. METHODS: A retrospective review of four institutions' database was performed to identify the PET-avid HCAs with clinico-pathological correlation. RESULTS: Nine patients with histological proven PET-avid HCA was identified. Eight out of 9 patients were female with a median age at diagnosis of 44 years. All patients' tumors with available histological subtyping (8/8) were HNF1-α mutated and had no inflammatory changes; 6 out the 9 lesions had prominent (>50%) steatotic changes. CONCLUSION:Hepatocellular adenomas, specifically the HNF1-α subtype, can cause false-positive PET findings when seeking to identify malignancy. Concomitantly, PET-CT may have the potential to identify the HCA histopathologic variant with the lowest malignant and hemorrhagic potential.
Authors: L James Wudel; Dominique Delbeke; David Morris; Michael Rice; Mary Kay Washington; Yu Shyr; C Wright Pinson; William C Chapman Journal: Am Surg Date: 2003-02 Impact factor: 0.688
Authors: Diamantis I Tsilimigras; Amir A Rahnemai-Azar; Ioannis Ntanasis-Stathopoulos; Maria Gavriatopoulou; Demetrios Moris; Eleftherios Spartalis; Jordan M Cloyd; Sharon M Weber; Timothy M Pawlik Journal: J Gastrointest Surg Date: 2018-08-14 Impact factor: 3.452
Authors: Willy Liu; Jean Delwaide; Noella Bletard; Philippe Delvenne; Paul Meunier; Roland Hustinx; Olivier Detry Journal: World J Hepatol Date: 2017-04-18